CHICAGO, April 19, 2024 — Three clinical trials investigating promising therapies for Alzheimer’s and other dementias are being propelled forward thanks to more than $2.9 million in new grant funding from
Part the Cloud, which provides strategic funding to advance promising investigational Alzheimer’s therapies into clinical trials. The funding brings Part the Cloud’s total investment to $67.9 million in 68 trials.
With this funding, research teams will advance innovative treatment strategies that focus on stopping one of the primary brain changes linked to Alzheimer’s and related dementia, protecting brain cells and improving cognition.
“By advancing promising investigational therapies into clinical trials, Part the Cloud has created a movement unlike any other in the Alzheimer’s and dementia space,” said Maria C. Carrillo, Ph.D., Alzheimer's Association chief science officer and medical affairs lead. “We are proud of the continued impact we are making to diversify the treatment pipeline and drive us toward a future of combination therapies and personalized medicine approaches for Alzheimer’s and other dementia.”
The recent Part the Cloud grant awardees include:
- Lawren VandeVrede, M.D., Ph.D., University of California, San Francisco: Study of a Tau Anti-sense Oligonucleotide in Corticobasal Syndrome (STACS).
- Jared Brosch, M.D., Indiana University: Niacin treatment of mild-moderate Alzheimer's disease.
- Joseph Foss, M.D., NeuroTherapia, Inc.: A Phase IIa study of NTRX-07 in Alzheimer's patients.
Started by philanthropist Michaela “Mikey” Hoag in 2012, Part the Cloud is specifically designed to accelerate translation of findings from the laboratory, through trials, into possible therapies — filling the gap in Alzheimer's drug development by providing essential support for early-phase clinical studies. This research program actively brings together government, academia, companies and philanthropists to support the efforts of researchers and accelerate science to achieve effective treatments.
“Through Part the Cloud, we have built a funding platform to combat Alzheimer’s disease and other dementias,” said Mikey Hoag. “With the continued innovation of this program and support from our generous donors, I’m confident we will end these diseases once and for all.”
With dementia affecting 50 million people worldwide, and nearly
7 million in the U.S. alone, there is an urgent need to identify therapies capable of slowing, preventing or reversing the brain cell damage inflicted by Alzheimer’s and other causes of dementia.
To learn more about Part the Cloud, including current and future funding opportunities, visit
alz.org/partthecloud.
About the Alzheimer's Association
The Alzheimer’s Association is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support. Our vision is a world without Alzheimer's and all other dementia®. Visit alz.org or call 800.272.3900.